Profile
Morningside Group is a venture capital firm based in Newton, Massachusetts, founded in 1986. The firm is led by a team of 12 professionals with expertise in life sciences, digital health, AI, materials, and technology. Morningside Group is known for its long-term outlook in company-building and its commitment to ethical investment practices. The firm also engages in charitable activities, supporting institutions like the Harvard T.H. Chan School of Public Health and the MIT Morningside Academy for Design.
The firm invests in companies with novel science and technology, focusing on sectors such as life sciences, digital health, and AI. Morningside typically participates in Series A and Series B rounds, with check sizes ranging from $5-10 million. The firm operates globally, tailoring its investments to dynamic market needs. Morningside Group also functions as a family office and engages in growth and expansion investments.
Notable investments by Morningside Group include AdvanCell - drug discovery, Mighty Therapeutics - drug discovery, Dermatic Health - decision/risk analysis, Ampa Health - therapeutic devices, and Valitor - biotechnology. These investments highlight the firm's focus on innovative ventures in the biotechnology and technology sectors.
Industry
Morningside Group Funds
| Name | Type |
|
|
|
Size | AUM | Launch date |
|---|---|---|---|---|---|---|---|
|
Morningside Ventures Fund IV
|
Venture Capital (VC)
|
Biotechnology
Healthcare Services
AI
Life Sciences
CleanTech
|
Pre-seed
Seed
Series A
|
North America
Europe
Asia
|
$5-10 m
|
—
|
November 2015
|
Contacts
Instant access on the web. Plans from $129/month — see pricing.